
BackgroundInternal quality control is commonly carried out using rule-based systems such as Westgard multirules and the exponentially weighted moving average. However, these methods may be slow to detect gradual drift and imprecision changes in current analyzers. Unsupervised anomaly detection algorithms, trained on in-control quality control data, provide an additional data-driven approach that does not require patient data.MethodsWe generate synthetic IQC data with four faults: a +2 SD step shift, a linear trend to +2 SD, an abrupt doubling of the SD, and intermittent ±4 SD outliers (3% of post-onset runs) on a standardized z-scale, including 54,000 QC-level series (12 analyte labels × 3 QC levels × 5 scenarios × 300 replications). We used Holm-corrected paired tests and bootstrap confidence intervals to summarise delay per replication (median across 12 analytes); outlier delay was calculated from the first injected outlier, and delay in fault-free streams served as the no-fault reference. A severity sweep changed the fault’s trajectory and size.ResultsStep shifts had median delays of 0.0–2.0 runs, while sudden imprecision increases had median delays of 0.5–3.5 runs, with CUSUM being the slowest. Delays from the initial injected outlier were 1.0 for EWMA, 12.5 for CUSUM, and 0.0 runs for Westgard, Isolation Forest, and One-Class SVM. The median delays for the trend were 19.8 (EWMA), 23.5 (Isolation Forest), 30.0 (Westgard), 31.5 (One-Class SVM), and 44.0 runs (CUSUM). Except for CUSUM, the trend delays were only roughly 2–7 runs shorter than the time to first alert in fault-free streams, and the false-alarm rates (2.2–5.2 per 100 analyte-runs) did not match. Most of the machine-learning discrimination was explained by engineered temporal features (imprecision AUC for Isolation Forest 0.93 with all features versus 0.70 with z and |z| only).ConclusionNo method was consistently the fastest; instead, performance varied by defect type and false-alarm operating point. Discrepancies in the false-alarm rate were a major factor in explaining apparent discrepancies between techniques for slowly developing trends. Validation using actual laboratory QC data is necessary because these standardized simulations do not show clinical benefit.
BackgroundCancerous inhibitor of PP2A (CIP2A) is a trimeric protein phosphatase inhibitor. CIP2A acts on the tumor suppressor PP2A, controlling cell survival and proliferation. Several studies have demonstrated that CIP2A is aberrantly overexpressed in both hematological cancers and solid tumors and may be a predictive biomarker for poor prognosis. On the other hand, there are several studies that show conflicting evidence. This comprehensive systematic review aims to evaluate the predictive significance of CIP2A in cancer.Methods34 studies published from 2013 to 2026, were selected for the examination of the potential relationship between CIP2A and various clinical milestones in solid and hematological cancers. Searches of PubMed, EBSCO (Medline) and Web of Science (core collection) were conducted until 01/06/2026. The Newcastle-Ottawa scale was used to assess risk of bias. Meta-analysis was performed to evaluate the use of CIP2A as a predictive biomarker for clinical outcome.ResultsAt 5 years, the random effects model revealed a significant difference between low and high CIP2A expression and overall survival (OS) (p < 0.001). At one and 5 years, there were significant differences in progression free survival (PFS) between low and high CIP2A expression (P = 0.001 and P < 0.001, respectively). Subgroup analysis revealed that, in the context of both the colorectal and breast cancer groups, there were significant differences between the low and high CIP2A groups at the five-year milestone and in CML and AML at 1 year.ConclusionElevated CIP2A expression at diagnosis was associated with poor overall survival and progression-free survival, although this association should be interpreted cautiously due to heterogeneity between cancer types, limited subgroup data, and methodological limitations. When compared to several other cancers, it was discovered that this association was stronger in specific cancers, such as leukemia, colorectal and breast cancer.
Corneal nerve status has gained prominence as a potential adjunctive biomarker for neurodegenerative and neurological diseases, as corneal small-fibre abnormalities can be detected in peripheral neuropathy and may precede conventional manifestations in certain conditions. Advances in in vivo confocal microscopy (IVCM) allow non-invasive, cellular-level assessments of corneal nerve alterations in real-time. Corneal nerve metrics have been associated with disease progression and severity. This review explores the role of corneal nerve status in the evaluation and monitoring of neurodegenerative and neurological diseases or conditions, including diabetic peripheral neuropathy (DPN), Parkinson’s disease (PD), mild cognitive impairment (MCI) and dementia, multiple sclerosis (MS), schizophrenia, amyotrophic lateral sclerosis (ALS), migraine, tauopathies, and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The strength and maturity of evidence vary substantially between conditions. DPN has the most established evidence base, with replicated cross-sectional and longitudinal studies showing reductions in corneal nerve fibre density, branch density and length, and evidence that corneal nerve loss may precede conventional manifestations of neuropathy. In MS, longitudinal studies demonstrate progressive corneal nerve loss associated with worsening disability. In PD, the extent of corneal nerve fibre loss correlates with severity of motor deterioration, cognitive impairment and development of autonomic dysfunction, although proposed applications in prodromal detection, disease phenotyping, and prognostication remain largely dependent on small, single-centre studies. Studies in MCI and dementia suggest potential diagnostic and prognostic utility, including comparisons with neuroimaging, but are largely derived from overlapping single-centre cohorts. Evidence in CIDP, migraine, ALS, and schizophrenia remains limited or conflicting, while evidence in tauopathies is predominantly pre-clinical. Overall, current literature supports corneal nerve parameters primarily as promising adjunctive rather than established diagnostic, prognostic, treatment-response biomarkers. Direct evidence that IVCM provides incremental diagnostic or prognostic value over established biomarkers remains limited. Furthermore, heterogeneity in confocal platforms, image acquisition, image sampling, and analytical methods must be considered in the interpretation across studies. Standardised acquisition and analysis protocols, prospective multicentre longitudinal studies, appropriate adjustment for confounders, and direct comparison with established biomarkers are necessary before broader clinical translation.
BackgroundAcute appendicitis in pregnancy often presents atypically, and diagnostic delay increases the risk of perforation. Concomitant biliary pathology can further obscure the clinical picture, particularly in late gestation.CaseA 19-year-old woman at 35 weeks’ gestation presented with 1 day of dull right lower quadrant pain with associated right upper quadrant discomfort. Laboratory testing showed leukocytosis (WBC 16.34 K/μL; neutrophils 82.8%) and a markedly elevated hs-CRP (239.21 mg/L). Ultrasound demonstrated an impacted gallbladder neck stone, but the appendix was not visualized. MRI identified an enlarged appendix (14 mm) with periappendiceal inflammation and moderate free fluid consistent with perforated appendicitis with peritonitis, and concurrently demonstrated imaging features of acute calculous cholecystitis with mild bile duct dilatation. Emergency laparoscopy confirmed a necrotic, leaking appendix with localized purulent peritonitis, and laparoscopic appendectomy was performed. Recovery was uncomplicated, and the pregnancy progressed to an uncomplicated vaginal delivery at 38 weeks’ gestation of a healthy newborn.ConclusionIn late pregnancy, overlapping right-sided abdominal pain may reflect concurrent surgical pathology. MRI can rapidly clarify diagnosis and guide timely operative management to reduce maternal-fetal risk.